EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Trends in antimicrobial resistance among Streptococcus pneumoniae from respiratory tract infections PROTEKT US Y1 and Y2



Trends in antimicrobial resistance among Streptococcus pneumoniae from respiratory tract infections PROTEKT US Y1 and Y2



Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 43: 127



Background: Resistance to antimicrobials among respiratory tract pathogens continues to be of major concern. PROTEKT US began in 2000 to longitudinally monitor resistance to key respiratory tract pathogens, including Streptococcus pneumoniae, across the USA. Methods: A total of 10,103 S. pneumoniae isolates in 2000-01 (Y1) and 10,012 in 2001-02 (Y2) were collected from across the USA. MICs and susceptibilities were determined according to NCCLS methodology. Macrolide-resistance mechanisms were detected by PCR. Results: In Y2 of PROTEKT US, the overall prevalence of resistance to penicillin (Pen-R) and erythromycin (Ery-R) in the US remained high. States with the largest increases in the percentage of Pen-R and Ery-R from Y1 to Y2 included Kentucky, Minnesota and Delaware, the largest reductions were seen in Oklahoma, West Virginia and Georgia. Telithromycin was highly active in vitro against S. pneumoniae isolated in Y1 and Y2 of PROTEKT US, with 99.6% and 99.9% of isolates susceptible (MIC

(PDF 0-2 workdays service: $29.90)

Accession: 035985207

Download citation: RISBibTeXText



Related references

Distribution across the USA of macrolide resistance and macrolide resistance mechanisms among Streptococcus pneumoniae isolates collected from patients with respiratory tract infections: PROTEKT US 2001-2002. Journal of Antimicrobial ChemoTherapy 54 Suppl 1: I17-I22, 2004

Antimicrobial resistance of Streptococcus pneumoniae recovered from respiratory tract infections of inpatients in Moscow. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 40: 109, 2000

Streptococcus pneumoniae serotypes and antimicrobial resistance in isolates from respiratory tract infections in Spain. Journal of Antimicrobial Chemotherapy 44(SUPPL A): 91, July, 1999

Activity of telithromycin against Streptococcus pneumoniae resistant to penicillin, macrolides and fluoroquinolones isolated from respiratory tract infections PROTEKT US year 2. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 43: 205, 2003

PspA family distribution, antimicrobial resistance and serotype of Streptococcus pneumoniae isolated from upper respiratory tract infections in Japan. Plos One 8(3): E58124-E58124, 2013

Antimicrobial resistance of Streptococcus pneumoniae and Haemophilus influenzae isolated from children with community-acquired respiratory tract infections in Central Poland. International Journal of Antimicrobial Agents 23(1): 39-43, 2004

Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients with respiratory tract infections in Germany from 1998 to 1999: results of a national surveillance study. Journal of Clinical Microbiology 39(3): 1187-1189, 2001

Prevalence of antimicrobial resistance in bacterial pathogens causing lower respiratory tract infections Results of the PROTEKT ITALY survey. Abstracts Of The Interscience Conference On Antimicrobial Agents & Chemotherapy. 43: 134, 2003

Antimicrobial resistance of Streptococcus pneumoniae recovered from respiratory tract infections of outpatients in Germany, 1998-1999 Results of a 20-center national surveillance study. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 39: 150, 1999

Antimicrobial resistance of 1,113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: Results of a 1-year (1996-1997) multicenter surveillance study. Antimicrobial Agents and Chemotherapy 43(2): 357-359, 1999

Antimicrobial resistance of 1,113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: results of a 1-year (1996-1997) multicenter surveillance study. The Spanish Surveillance Group for Respiratory Pathogens. Antimicrobial Agents and ChemoTherapy 43(2): 357-359, 1999

Resistance trends in Streptococcus pneumoniae (PROTEKT years 1-3 [1999-2002]). Journal of ChemoTherapy 16 Suppl 6: 19-33, 2005

Trends in antibacterial resistance in Streptococcus pneumoniae and activity of telithromycin: PROTEKT US years 1-5. 2006

Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4. Annals of Clinical Microbiology and Antimicrobials 7(): 1-1, 2008

Demographic analysis of antimicrobial resistance among Streptococcus pneumoniae: worldwide results from PROTEKT 1999-2000. International Journal of Infectious Diseases 9(5): 262-273, 2005